In a quest to address novel and previously intractable targets, drug discovery is undergoing a rapid transition from traditional small molecule and antibody approaches to a more diverse range of therapeutic modalities, including RNA therapeutics and antibody-drug conjugates. These exciting new approaches raise challenges as well as opportunities, with a critical need for development of novel drug delivery systems and for advanced analytical methods.
Medicines Discovery Catapult has worked with SEDA Pharmaceutical Development Services to bring clarity to the scope of the term ‘complex medicines’.
